AMD3100 modulates the secretome responses of human Mesenchymal Stromal Cells but not their inhibitory effect on T cell proliferation Authors: Rhett N. Parr, Sara Temple, Maya Brown, Denton Lord, Isabella Hogan, Keenan Hogan, Lawson Blake, Yenamala U. Reddy, Devi Rajan, Peiman Hematti, Raghavan Chinnadurai Published: 2026 ABSTRACT AMD3100 (Plerixafor) is being utilized in clinic for the mobilization of Hematopoietic Stem Cell (HSCs) from bone marrow into peripheral blood to facilitate peripheral blood sourced HSC transplantation. It is important to identify the immunomodulatory role of AMD3100 in bone marrow niche. We have investigated the effect of AMD3100 on culture expanded human bone marrow derived Mesenchymal Stem/Stromal Cells (BM MSCs) which are non-hematopoietic cells of the marrow niche. AMD3100 does not modulate the metabolic activity of BM MSCs. However, multiplex secretome analysis demonstrated that AMD3100 alters the specific innate secretory molecules of BM MSCs. AMD3100 also amplifies the chemokine secretion of MSCs upon stimulation with IFNγ and TNFα. Flow cytometry analysis identified that AMD3100 augments IFNγ and TNFα mediated induction of the immunosuppressive enzyme Indoleamine 2, 3 Dioxygenase (IDO) in human BM MSCs. Coculture functional analysis of human BM MSCs with Peripheral Blood Mononuclear Cells (PBMCs) has demonstrated that BM MSCs dose dependently inhibits the T cell proliferation and exogenous addition of AMD3100 did not modulate this inhibition. In contrast, secretory analysis showed that AMD3100 modulates the secretory responses of BM MSCs and activated PBMC cocultures. These results suggest that AMD3100 modulates the immunomodulatory effect of BM MSCs and alters the soluble milieu of marrow niche.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-51923-y. Introduction AMD3100 (Plerixafor, Mozobil) is currently being used in the clinic for mobilization of hematopoietic stem cells (HSCs) from bone marrow to peripheral blood to facilitate Hematopoietic Stem Cell Transplantation (HSCT)1–3. Specifically, AMD3100 mediated mobilization of HSCs is widely used for autologous HSCT in patients with Non-Hodgkin’s Lymphoma (NHL) or Multiple Myeloma (MM)4–7. AMD3100 antagonizes the CXCR4 receptor and disrupts CXCR4/SDF-1 (CXCL12) axis in the bone marrow niche, thereby mobilizing HSCs from the marrow into the peripheral blood8. Collected and mobilized HSCs in the peripheral blood are used as the graft source for autologous HSCT. In addition to the application as a HSC mobilizer, AMD3100 also has other potential biological properties and therapeutic values. AMD3100 shows benefit in treating WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis) related panleukopenia which is caused by genetic mutations in CXCR49. In addition, AMD3100 is shown to mitigate radiation-induced injury and fibrosis in the preclinical animal models and thus exhibit protection against ionizing radiation10,11. AMD3100 has also been demonstrated exhibiting anti-tumor activities in the preclinical models of cancer such as Primary Lymphoma of the Central Nervous System12, Glioblastoma13, Cervical cancer14, Hepatocellular carcinoma15, Prostate cancer16, Breast cancer17, Melanoma18, Colon cancer19 and Leukemia20. AMD3100 also provides benefits in combination treatment with immune checkpoint inhibitors via mitigating immunosuppressive tumor microenvironment and promoting integrated immune responses21,22. In addition to its potential anti-tumor activities, AMD3100 is shown to reduce the severity of inflammation in the preclinical models of autoimmune disorders such as Autoimmune collagen-induced arthritis (CIA)23. The versatile therapeutic potential of AMD3100 is due to its numerous cellular targets other than HSCs, which include lymphocytes24,25, neural stem cells26, myeloid lineage cells27, endothelial progenitor cells28 and epithelial cells29. Thus, it is of translational interest to identify additional cellular targets of AMD3100 in the bone marrow niche cellular components other than HSCs. Mesenchymal Stem/Stromal Cells (MSCs) are the non-hematopoietic cells of the marrow niche that support hematopoiesis, possess immunomodulatory and regenerative properties and regulates the marrow immune responses30,31. Bone Marrow MSCs (BM MSCs) are defined with cell markers positive for CD73, CD105, CD90 and a lack of CD4532,33. BM MSCs differentiate into adipocyte, osteocyte and chondrocytes which are the principal components of the bone and thus they are also distinguished as non-hemopoietic stem cells of the niche32,33. In addition, MSCs possess anti-inflammatory properties and can essentially block inflammatory immune cell amplifications and their secretory products34. It is necessary to define the immunomodulatory effect of AMD3100 on BM MSCs due to two significant reasons, (A) BM MSCs play a key role in regulating the immunomodulatory microenvironmental niche and (B) BM MSCs persist in the marrow even after HSCT and do not get engrafted from the donor HSC graft and thus are of recipient origin. In support of this phenomenon, previous studies have shown that MSCs derived from BM aspirates of HSCT patients are exclusively of recipient origin35–38. Thus, BM MSCs persist in the marrow during the course of pre and post HSCT and the effect of AMD3100 on their immunomodulatory properties needs to be evaluated. In the present study we investigated the effect of AMD3100 on the potency and functionality of ex vivo cultured MSCs through three major strategies. In the first strategy, the effect of AMD3100 on BM MSCs’ innate secretory breadth and fitness were evaluated. In the second strategy, the effect of AMD3100 on BM MSC’s responsiveness to exogenous inflammatory cues were evaluated. In the third strategy, AMD3100 effect on the anti-inflammatory properties of MSCs on T cells in the presence of AMD3100 was investigated through functional coculture analysis. Materials and methods Human bone marrow derived MSCs and Peripheral Blood Mononuclear Cells Isolation of Human Peripheral Blood Mononuclear Cells (PBMCs) was made from the discarded and deidentified healthy leukapheresis products. Discarded and deidentified products obtained from cell processing facility at the Medical College of Wisconsin (does not qualify as human subjects research according to the institutional review board guidelines at the Medical College of Wisconsin). PBMCs were isolated through Ficoll™ density gradient (Cytiva, USA). Bone marrow derived MSCs (BM MSCs) were isolated from the discarded and de-identified bone marrow filters of healthy donors undergoing bone marrow harvest (does not qualify as human subjects research according to the institutional review board guidelines at the Medical College of Wisconsin). Experiments were performed at Mercer University. BM MSCs were cultured in 1X alpha-Minimal Essential Medium (Corning, USA) with 5% human platelet lysate (MillCreek Life sciences, USA) and 100 IU/ml penicillin/streptomycin/amphotericin B (Corning, USA). BM MSC identity was confirmed for the expression of CD73, CD105, CD90, CD44 and lack of CD45 as described previously39. Experiments were performed on four unique BM MSC donors from passages 3 to 6 and at the time of experimentations, the BM MSCs were derived from 70% confluency. Each experiment was repeated at least 4 independent times with 4 independent MSC and PBMC donors. PBMC donors are independent from MSC donors. Analyses were performed in a paired manner, with each MSC donor serving as its own control for AMD3100 response. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay BM MSCs were seeded in 96-well plates at identical densities. Following incubation with AMD3100 (Sigma Aldrich, USA) at specified time points, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed. At the time of assay, thiazolyl blue tetrazolium (TCI America, USA) was added to the cells, and incubated for 5 h. After the five-hour incubation, supernatants were carefully removed, and the formazan crystals were dissolved in Dimethyl Sulfoxide. Optical densities were measured at the wavelength of 560 nm and subtracted with the values from reference wavelength of 670 nm. Stimulation of BM MSCs with IFNɣ and TNF⍺ with IDO expression analysis BM MSCs were incubated with respective concentrations of human recombinant IFNɣ and TNF⍺ (Biolegend, USA). After incubation, cells were harvested and subjected to IDO expression analysis. Supernatants were collected for chemokine secretome analysis. BD Cytofix™ and Cytoperm™ procedure (BD Biosciences, USA) was performed to detect intracellular IDO expression with the IDO PE antibody (Clone eyedio) (Invitrogen, USA). Stained cells were acquired in BD FACS Aria II flow cytometer, and the results were analyzed in Flow Jo software. MSC and PBMC coculture analysis with AMD3100 BM MSCs and PBMCs activated with anti-CD3(1 µg/ml), anti-CD28(1 µg/ml) antibodies (Biolegend, USA) were cocultured with indicated ratios. BM MSC numbers were kept variable while PBMC numbers (0.1 × 106 cells) were kept constant in the cocultures. AMD3100 was added in the respective conditions at the initiation of the cocultures. After 4 days of incubation, PBMCs were stained with CD3 APCCy7 (Clone SK7) (Biolegend, USA) and Ki67 PE (Clone B56) (BD Biosciences, USA) antibodies according to manufacturer instructions following Intracellular BD Cytofix™ and Cytoperm™ procedure (BD Biosciences, USA). Stained cells were acquired in BD FACS Aria II flow cytometer, and the results were analyzed in Flow Jo software. Multiplex secretome analysis Supernatants from the relevant investigational conditions were preserved at -80 C. Supernatants were thawed and centrifuged at 2000 rpm for 15 min to get rid of the debris. Subsequently, appropriate supernatants were analyzed with either chemokine multiplex secretory analysis or 33 plex human immune response multiplex secretory analysis. Chemokine multiplex panel includes CXCL9, CXCL10, CXCL11, CCL8, CCL13, CCL20, CCL21, CCL7, CCL16, CXCL14, CCL11 CXCL1, and CX3CL1 (Biotechne, USA). 33 plex secretory analysis includes GMCSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12p70, IL-13, IL-18, TNF⍺, IL-9, IL-10, IL-17 A (CTLA-8), IL-21, IL-22, IL-23, IL-27, IFN⍺, IL-1⍺, IL-1RA, IL-7, IL-15, IL-31, Eotaxin (CCL11), GRO-⍺ (CXCL1), IP-10 (CXCL10), MCP-1 (CCL2), MIP-1⍺ (CCL3), MIP-1β(CCL4), RANTES (CCL5), SDF-1⍺ (ProcartaPlex, Thermofisher, USA). Multiplex Acquisition was performed according to the manufacturer’s instructions in Luminex-200 instrument and analysis was done using Luminex xMAP software. Each secretory analyte was quantified as picogram/milliliter (pg/ml). Statistics Area Under Curve (AUC) and comparison of groups were analyzed with the GraphPad Prism 10.0 software. Appropriate statistical tests including ratio paired t test and one way ANOVA Dunnett’s multiple comparisons test were performed. MSC Donors were matched for their identifying responses with concentrations of AMD3100 and/or IFNγ + TNFα. Given the sample size (n = 4), formal correction for multiple comparisons was not applied due to limited statistical power and exploratory nature of this study. Statistical significance was confirmed with the p value of ≤ 0.05 as significant and p value of ≥ 0.05 as non-significant (ns). In some situations, p values were represented with their conversion as Negative Logarithmic P(NLP) values. Results AMD3100 does not modulate the metabolic activity of human BM MSCs Human BM MSCs derived from four independent donors were seeded in similar densities and subsequently cultured with escalating doses of AMD3100. MTT assays were performed on days 1, 2, and 3 to assess the metabolic activity and growth fitness of MSCs. This assay measures the reduction of tetrazolium dye to formazan, a process dependent on cellular energetics and NAD(P)H-dependent oxidoreductase enzyme activity40. Our results demonstrate that MSC’s reduction of tetrazolium dye is increased kinetically from day 1 to day 3 which indicates their metabolic growth potential (Fig. 1A). However, dose dependent addition of AMD3100 does not modulate BM MSC’s MTT activity in all the time points (Fig. 1A). These results suggest that AMD3100 neither modulates the metabolic activity nor induces cytotoxicity in human BM MSCs. Fig. 1Impact of AMD3100 on BM MSC’s metabolic activity and innate secretory analytes. (A) BM MSCs were seeded in an identical density and incubated with indicated concentrations of AMD3100 (0,1,10, 100µM). MTT assays were performed on the specified days post incubation. MTT activity was measured in colorimetry as optical density. (B) BM MSCs seeded in variable densities were incubated with and without AMD3100 (0, 100µM). Four days later supernatants were collected and subjected to multiplex secretome analysis for 33 analytes. Six analytes that show substantial secretions based on MSC densities are shown in the conditions with and without AMD3100 (0, 100µM). The remaining 27 analytes are shown in supplementary Fig. 1. (C) AUC of each analyte shown in (B) was determined from the conditions of with and without AMD3100. AUC values were subjected to ratio paired t test for statistical significance matching the donors. P < 0.05 indicates the statistical significance. Cumulative results are shown from BM MSCs derived from four independent donors. Impact of AMD3100 on BM MSC’s metabolic activity and innate secretory analytes. (A) BM MSCs were seeded in an identical density and incubated with indicated concentrations of AMD3100 (0,1,10, 100µM). MTT assays were performed on the specified days post incubation. MTT activity was measured in colorimetry as optical density. (B) BM MSCs seeded in variable densities were incubated with and without AMD3100 (0, 100µM). Four days later supernatants were collected and subjected to multiplex secretome analysis for 33 analytes. Six analytes that show substantial secretions based on MSC densities are shown in the conditions with and without AMD3100 (0, 100µM). The remaining 27 analytes are shown in supplementary Fig. 1. (C) AUC of each analyte shown in (B) was determined from the conditions of with and without AMD3100. AUC values were subjected to ratio paired t test for statistical significance matching the donors. P < 0.05 indicates the statistical significance. Cumulative results are shown from BM MSCs derived from four independent donors. AMD3100 modulates specific innate secretory molecules of human BM MSCs We investigated the effect of AMD3100 on the innate secretome fitness and breadth of BM MSCs. Analyzing the innate secretome of MSCs is limited due to the difficulty of selecting an appropriate cell density due to donor-to-donor variation. Seeding cells at low density may result in failure to detect low-level secretory analytes, whereas high seeding density can cause over confluency, leading to cell death and detachment from the culture. To overcome this limitation, MSCs from four independent donors were seeded at gradually decreasing densities (12,500, 6,250, 3,125, and 0 cells per well), cultured in the presence or absence of AMD3100, and the supernatants were collected for secretome analysis. Here, the 0 condition corresponds to media without MSCs and serves as background control, enabling unbiased detection of both high- and low-abundance secretory analytes and the effect of AMD3100. Among the 33 secretory analytes examined, 6 exhibited secretion patterns that were dependent on the cell density of MSC cultures (Fig. 1B) (Fig.S1). Area under the curve (AUC) analysis identified that, among the six analytes, secretion of SDF-1⍺ and GRO-⍺ was further upregulated by AMD3100 at statistically significant levels (Fig. 1C). AMD3100 increased IL-8 secretion and reduced MCP-1 and IL-6 secretion, although these effects did not reach statistical significance and instead showed a statistical trend (Fig. 1C). Altogether, our results suggest that AMD3100 upregulates specific innate secretory molecules in BM MSCs. AMD3100 modulates specific chemokine responses of BM MSCs to exogenous inflammatory cues MSCs’ functionality largely depends on their responsiveness to exogenous cues, including their ability to upregulate immune effector molecules41–43. Previous studies have shown that MSCs’ responses to inflammatory cues, such as IFNγ and TNFα, and the subsequent upregulation of effector chemokines, can serve as a measure of their functionality40. Since chemokines can influence the immune cellular composition of the bone marrow niche, we investigated the effect of AMD3100 on modulating IFNγ and TNFα mediated chemokine upregulation in BM MSCs. BM MSCs from four independent donors were seeded at a fixed density and stimulated with escalating concentrations of both IFNγ and TNFα (0, 0.4 + 0.4, 4 + 4, 40 + 40 ng/ml) and AMD3100 (0, 1, 10, 100µM). The supernatants were then analyzed for 13 chemokines using multiplex analytical methods. Thirteen chemokines were selected for analysis based on our previous studies, which showed that they are upregulated by IFNγ in combination with TNFα40. Consistent with the previous reports, the present study also demonstrated that IFNγ and TNFα dose dependent stimulation upregulates all thirteen chemokines which includes CXCL9, CXCL10, CXCL11, CCL8, CCL13, CCL20, CCL21, CXCL1, CCL7, CCL16, CXCL14, CCL11, CX3CL1 (Fig. 2A). Comparative AUC analysis identified that AMD3100 further upregulates CXCL9 and CXCL10 in all the tested concentrations of 1, 10 and 100µM with statistical significance (Fig. 2B and C). CXCL11, CCL8 and CCL13 are upregulated in the AMD3100 concentrations of 10 and 100 µM while CCL20 and CCL21 are further upregulated in the highest concentration of 100 (Fig. 2B and C). None of the other 6 chemokines are upregulated by AMD3100 (Fig. 2B and C). These results suggest that AMD3100 synergistically upregulates a distinct set of chemokines with varying sensitivity when combined with IFNγ and TNFα, but not all chemokines are affected. Fig. 2BM MSC’s chemokine responses to inflammatory cues and AMD3100. BM MSCs were seeded in an identical density and subsequently stimulated with the indicated concentrations of IFNγ, TNFα and AMD3100. After 48 h of incubation, the supernatants were collected and subjected to multiplex analysis for the quantification of 13 chemokines. (A) Individual chemokine responses to IFNγ and TNFα (0, 0.4 + 0.4, 4 + 4, 40 + 40 ng/ml) in the presence of various AMD3100. Concentrations (0,1,10, 100µM) are shown. Chemokines are quantified as pg/ml. Cumulative results are shown from BM MSCs derived from four independent donors. (B) The AUC of each chemokine, based on its dose-dependent secretion in response to IFNγ and TNFα, was calculated and charted across the indicated AMD3100 concentrations (0,1,10, 100µM). (C) AUC values identified in (B) were subjected to one way ANOVA Dunnett’s multiple comparisons test to identify the statistical significance of AUC comparisons between 0 vs. 1, 0 vs. 10, and 0 vs. 100 µM AMD3100 with donor matching. Identified P values were converted into negative logarithmic p-values (NLP) and displayed as a heat map. Significant differences are indicated by asterisks. BM MSC’s chemokine responses to inflammatory cues and AMD3100. BM MSCs were seeded in an identical density and subsequently stimulated with the indicated concentrations of IFNγ, TNFα and AMD3100. After 48 h of incubation, the supernatants were collected and subjected to multiplex analysis for the quantification of 13 chemokines. (A) Individual chemokine responses to IFNγ and TNFα (0, 0.4 + 0.4, 4 + 4, 40 + 40 ng/ml) in the presence of various AMD3100. Concentrations (0,1,10, 100µM) are shown. Chemokines are quantified as pg/ml. Cumulative results are shown from BM MSCs derived from four independent donors. (B) The AUC of each chemokine, based on its dose-dependent secretion in response to IFNγ and TNFα, was calculated and charted across the indicated AMD3100 concentrations (0,1,10, 100µM). (C) AUC values identified in (B) were subjected to one way ANOVA Dunnett’s multiple comparisons test to identify the statistical significance of AUC comparisons between 0 vs. 1, 0 vs. 10, and 0 vs. 100 µM AMD3100 with donor matching. Identified P values were converted into negative logarithmic p-values (NLP) and displayed as a heat map. Significant differences are indicated by asterisks. AMD3100 upregulates Indoleamine 2,3 Dioxygenase in combination with IFNγ and TNFα BM MSCs’ immunosuppressive functionality is largely dependent on the upregulation of tryptophan metabolizing enzyme, indoleamine 2,3 dioxygenase (IDO) and is widely considered as the potency metrics of MSCs’ functionality43,44. We investigated the effect of AMD3100 along with IFNγ and TNFα in inducing IDO expression. MSCs from four independent donors were stimulated with escalating doses of IFNγ and TNFα in combination with varying doses of AMD3100. Flow cytometry analysis for IDO expression has demonstrated that AMD3100 independently does not induce IDO while synergistically inducing its expression in conjunction with IFNγ and TNFα (Fig. 3A and B). The synergistic effect of AMD3100 is observed only with IFNγ and TNFα stimulation at concentrations of 4 + 4 and 0.4 + 0.4 (ng/ml) and is not observed at the highest concentrations of IFNγ and TNFα (Fig. 3A and B). Altogether these results suggest that AMD3100 acts as an adjuvant for IFNγ and TNFα mediated upregulation of IDO in human BM MSCs. Fig. 3Effect of AMD3100 on BM MSC’s IDO expression. BM MSCs were stimulated with the indicated concentrations of IFNγ and TNFα (0, 0.4 + 0.4, 4 + 4, 40 + 40 ng/ml). AMD3100 (0,1,10, 100µM) was also added with the stimulation cocktails at indicated concentrations. 48 h later, cells were harvested and stained with fluorochrome tagged anti-human IDO antibodies. The stained cells were analyzed in flow cytometer. (A) Representative histogram overlays are shown for IDO expression among the dose dependent stimulation of IFNγ and TNFα with the indicated concentrations of AMD3100. (B) Mean Fluorescent Intensities (MFI) of IDO is cumulatively shown among the dose dependent stimulations of IFNγ and TNFα with the indicated concentrations of AMD3100. Cumulative results are shown from BM MSCs derived from four independent donors. Effect of AMD3100 on BM MSC’s IDO expression. BM MSCs were stimulated with the indicated concentrations of IFNγ and TNFα (0, 0.4 + 0.4, 4 + 4, 40 + 40 ng/ml). AMD3100 (0,1,10, 100µM) was also added with the stimulation cocktails at indicated concentrations. 48 h later, cells were harvested and stained with fluorochrome tagged anti-human IDO antibodies. The stained cells were analyzed in flow cytometer. (A) Representative histogram overlays are shown for IDO expression among the dose dependent stimulation of IFNγ and TNFα with the indicated concentrations of AMD3100. (B) Mean Fluorescent Intensities (MFI) of IDO is cumulatively shown among the dose dependent stimulations of IFNγ and TNFα with the indicated concentrations of AMD3100. Cumulative results are shown from BM MSCs derived from four independent donors. AMD3100 does not modulate human BM MSCs’ inhibitory effect on T cell proliferation We investigated the effect of AMD3100 in modulating BM MSC’s immunomodulatory effect on T cells. Human BM MSCs derived from four independent donors were cultured with anti-CD3 and anti-CD28 stimulated peripheral blood mononuclear cells (PBMCs) at varying ratios and in the presence of different concentrations of AMD3100. The magnitude of T cell proliferation was quantified in flow cytometer by evaluating the percentage of CD3 + Ki67+ T cells. Our results demonstrate that BM MSCs dose dependently inhibit T cell proliferation as identified by the reduction in % of CD3 + Ki67+ T cell populations (Fig. 4A). However, AUC analysis demonstrated that AMD3100, at all tested concentrations, have no effect on the inhibitory effect of human BM-MSCs on T-cell proliferation (Fig. 4B and C). Fig. 4Impact of AMD3100 on BM MSC’s inhibitory function on T cell proliferation. BM MSCs were cocultured with anti-CD3 and anti-CD28 activated PBMCs at the indicated ratios in the presence of specified AMD3100 concentrations (0,1,10, 100µM). Four days later, T cell proliferation was quantified in flow cytometer by determining the percentage of CD3 + Ki67+ populations. (A) Representative flow cytometry plots are shown with gates determining the percentage of CD3 + and Ki 67 + populations. (B) Dose-dependent effect of BM MSCs with the indicated concentrations of AMD3100 in inhibiting T-cell proliferation (%CD3 + Ki67+) is shown. (C) The AUC of each curve in (B) was identified and plotted with the concentrations of AMD3100. One way ANOVA Dunnett’s multiple comparisons test was performed to identify the statistical significance of AUC comparisons between 0 vs. 1, 0 vs. 10, and 0 vs. 100 µM AMD3100 with donor matching. Cumulative results are shown from BM-MSCs derived from four independent donors. Impact of AMD3100 on BM MSC’s inhibitory function on T cell proliferation. BM MSCs were cocultured with anti-CD3 and anti-CD28 activated PBMCs at the indicated ratios in the presence of specified AMD3100 concentrations (0,1,10, 100µM). Four days later, T cell proliferation was quantified in flow cytometer by determining the percentage of CD3 + Ki67+ populations. (A) Representative flow cytometry plots are shown with gates determining the percentage of CD3 + and Ki 67 + populations. (B) Dose-dependent effect of BM MSCs with the indicated concentrations of AMD3100 in inhibiting T-cell proliferation (%CD3 + Ki67+) is shown. (C) The AUC of each curve in (B) was identified and plotted with the concentrations of AMD3100. One way ANOVA Dunnett’s multiple comparisons test was performed to identify the statistical significance of AUC comparisons between 0 vs. 1, 0 vs. 10, and 0 vs. 100 µM AMD3100 with donor matching. Cumulative results are shown from BM-MSCs derived from four independent donors. AMD3100 modulates the secretome responses of BM MSCs and activated PBMC coculture We investigated the functional modulation of AMD3100 on the secretome responses of BM MSCs and activated PBMCs. Supernatants of human BM MSCs cultured with anti-CD3 and anti-CD28 stimulated PBMCs at varying ratios and in the presence and absence of AMD3100 were analyzed for 33 secretory analytes. AUC analysis identified 12 analytes that showed statistically significant differences in their responses in the presence versus absence of AMD3100, whereas AMD3100 had no effect on the remaining 21 analytes (Fig. 5A and B) (Fig. S2). Among these 12 analytes, two distinct patterns of modulation were observed. Increased AUC is observed for GRO alpha and MCP-1 in the cocultures with AMD3100 which suggests that AMD3100 increases the secretion of these analytes in BM MSC and activated PBMC cocultures (Fig. 5C). In contrast, the AUC for 10 analytes (IL-1β, GMCSF, IL-9, IFNγ, IL1RA, IL-5, TNFα, IL-21, IL-1⍺, IL-18) are decreased in the BM MSC and activated PBMC cocultures with AMD3100 (Fig. 5C). Although AMD3100-mediated reductions in secretion are observed across these 10 analytes in BM MSC and activated PBMC cocultures, we performed a percentage reduction analysis to determine its specific effect on MSC mediated inhibition of activated PBMC secretion. In this approach, analyte concentrations were normalized to 100% in PBMC cultures (with and without AMD3100) in the absence of MSCs, and relative reductions were calculated accordingly. This analysis identified that AMD3100 increases the sensitivity of MSCs in inhibiting IL-21 and TNFα secretion in activated PBMCs, but not other analytes (Fig. S3). This analysis also identified that the reduction in the secretion of remaining 8 other analytes is due to the direct effect of AMD3100 on PBMCs irrespective of MSCs. Altogether, these results indicate that AMD3100 modulates the secretory responses of MSC and activated PBMC cocultures, both by directly acting on PBMCs and, at least in part, by enhancing the inhibitory function of MSCs on activated PBMCs. Fig. 5Secretome responses of BM MSC and PBMC coculture with AMD3100. BM MSCs were cocultured with anti-CD3 and anti-CD28 activated PBMCs at the indicated ratios in the presence of specified AMD3100 concentrations (0, 100mM). Four days later, Supernatants were collected and subjected to multiplex secretome analysis for the quantification of 33 analytes. (A) Hierarchical statistical significance of AUC comparisons of 33 analytes between 0 and 100 µM AMD3100 conditions is shown with negative logarithmic p-values (NLP). Significant differences are indicated by a black box. AUC values were subjected to ratio paired t test for statistical significance matching the donors. (B) Twelve analytes that show statistical significance between the conditions of with and without AMD3100 are shown as spaghetti plots. The remaining analytes are shown in Supplementary Figure 2. (C) AUCs of 12 analytes that showed statistical significance between 0 and 100 mM AMD3100 conditions are pairwise plotted. Cumulative results are shown from BM MSCs derived from four independent donors. Secretome responses of BM MSC and PBMC coculture with AMD3100. BM MSCs were cocultured with anti-CD3 and anti-CD28 activated PBMCs at the indicated ratios in the presence of specified AMD3100 concentrations (0, 100mM). Four days later, Supernatants were collected and subjected to multiplex secretome analysis for the quantification of 33 analytes. (A) Hierarchical statistical significance of AUC comparisons of 33 analytes between 0 and 100 µM AMD3100 conditions is shown with negative logarithmic p-values (NLP). Significant differences are indicated by a black box. AUC values were subjected to ratio paired t test for statistical significance matching the donors. (B) Twelve analytes that show statistical significance between the conditions of with and without AMD3100 are shown as spaghetti plots. The remaining analytes are shown in Supplementary Figure 2. (C) AUCs of 12 analytes that showed statistical significance between 0 and 100 mM AMD3100 conditions are pairwise plotted. Cumulative results are shown from BM MSCs derived from four independent donors. Discussion Although AMD3100 is not widely used to mobilize HSCs in healthy individuals, it is approved for the mobilization of HSCs in patients with MM and NHL undergoing autologous HSCT45–47. Preclinical and clinical studies have demonstrated that AMD3100 is an effective mobilizing agent, generating peripheral blood grafts containing sufficient numbers of HSCs to support successful autologous HSCT48–51. However, it is important to note that the cellular composition of peripheral blood grafts mobilized with AMD3100 differs from that achieved with standard G-CSF mobilization52,53. In addition to increasing HSC content in peripheral blood, AMD3100 also enhances the mobilization of T cells, NK cells, neutrophils, and dendritic cells54–57. Animal studies have further shown that even when T-cell egress from secondary lymphoid organs is blocked, AMD3100 still increases lymphocyte levels in peripheral blood, suggesting that AMD3100 mobilizes T cells directly from the bone marrow27. These findings suggest that additional cellular components within the bone marrow niche may contribute to the activation and trafficking of immune cells, such as T cells, from the marrow to the peripheral blood following AMD3100 treatment. Our results demonstrate that AMD3100 significantly modifies MSC’s secretome. This altered MSC’s secretory profile provides a potential mechanistic explanation for how AMD3100 may promote the mobilization of immune cells, including lymphocytes, dendritic cells, and monocytes. Our data further demonstrate that AMD3100 activates MSCs to enhance the secretion of these analytes, providing a rationale that AMD3100-mediated activation of MSCs may underlie the enriched immune cell composition observed in AMD3100-mobilized peripheral blood grafts. Importantly, this immune-rich graft composition has been shown to be beneficial for patients undergoing autologous HSCT, as it enhances immune reconstitution and anti-disease activity58–60. Chemokines are guiding molecules that regulate leukocyte trafficking and homeostasis during health and disease resolution. Previous studies have shown that MSC functionality largely depends on their capacity to secrete chemokines40,61,62. Our results demonstrate that AMD3100 increases the chemokine secretion capacity of MSCs. Importantly, this effect is selective, as not all chemokines were significantly upregulated; only specific chemokines, including CXCL9, CXCL10, CXCL11, CCL8, CCL13, CCL20 and CCL21, showed statistically significant increases. Collectively, these chemokines may regulate the trafficking of immune cell populations to the bone marrow niche and thereby enhance immune surveillance against MM and NHL malignant cells. In addition to leukocyte trafficking, chemokines play multiple roles, including lymphoid development, tissue maintenance, angiogenesis, and immune modulation, such as macrophage polarization63–66. Thus, AMD3100 mediated enhancement of MSC derived chemokine secretion may contribute to improved disease-free survival in patients through these diverse biological functions. MSC’s immunomodulatory functions largely depends on their responsiveness to exogenous inflammatory cues and the upregulation of Indoleamine 2,3 Dioxygenase an anti-inflammatory enzyme of the Tryptophan metabolic pathway43,44. In addition, several studies utilize MSC’s responsiveness to inflammatory cues and the upregulation of IDO as a surrogate measure of their potency and functionality34,42. Our results show that AMD3100 mediated increasing of MSCs’ responsiveness to inflammatory cues and the upregulation of IDO suggests that AMD3100 can significantly improve the anti-inflammatory functionality of MSCs. We also noted that at the higher concentrations of inflammatory cues, AMD3100 effect is not seen with IDO induction which suggests that AMD3100 could act as an adjuvant to MSC’s responsiveness to mild physiological cues in the marrow niche. Although we observed that AMD3100 increases IDO expression on MSCs with inflammatory cues, it does not have a significant impact on MSC mediated inhibition of T cell proliferation. It is entirely possible that AMD3100 potentially induces compensatory metabolic pathways in PBMCs or alter the bioavailability of kynurenine metabolites that might mitigate MSC and IDO mediated inhibition of T cell proliferation. This can be further defined in future studies. However, we observed that AMD3100 modulates the secretome responses of BM MSCs and activated PBMC cocultures, specifically with the enhanced inhibition of 10 analytes (IL-1β, GMCSF, IL-9, IFNγ, IL1RA, IL-5, TNFα, IL-21, IL-1⍺, IL-18). We noted two phenomena here: (1) AMD3100 decreases the secretion of analytes in MSC and activated PBMC cocultures irrespective of MSCs. (2) AMD3100 enhances the sensitivity of MSC mediated inhibition of PBMC secretion. Both phenomena provided insights on the AMD3100 mediated cumulative modulation of secretome responses on both MSCs and PBMCs independently and also together. In addition, our results also provided insights that although AMD3100 does not substantially impact MSC mediated inhibition of primary T cell responses such as proliferation, instead modulating its effector functions such as secretion of some analytes but not all. In addition, we also noted that AMD3100 increases the secretion of GRO-⍺ and MCP-1 in MSC and activated PBMC cocultures. In the present study the effect of AMD3100 on the secretory functions of MSCs were analyzed using three different approaches (1) innate secretome analysis, (2) IFN𝛾+TNF⍺ induced secretome analysis. and (3) Secretory responses of the MSC and PBMC cocultures. All these data collectively identified AMD3100 induced secretory characterization of MSCs with the identification of multiple analytes. MSCs’s mechanism of action do not rely on a single effector pathway or molecule, rather they result from the cumulative action of a network of effector mediators30. The identification of AMD3100 induced secretome in the present study provides further insights that multiple secretory molecules cumulatively modulate the marrow microenvironment. In addition, these results further suggest that AMD3100 mediated MSC’s immunomodulation is largely through soluble secretory molecules and regulate the marrow microenvironmental milieu. Previous studies have shown that only a part of MSC populations expresses high levels of CXCR467,68. In addition, it is reported that BM MSCs loses chemokine receptor expression after 12–16 passages69. Another study showed that CXCR4 expression is regulated on BM MSCs, and further demonstrated that BM MSCs do not express CXCR4 on their surface but excessive amounts of their expression can be detected through intracellular staining70. We found that early passage BM MSCs (passage 3 to 6) exhibit undetectable CXCR4 expression on the cell surface, while intracellular CXCR4 expression is detectable (Fig. S4). These provide hypothetical explanations on the action of AMD3100 on BM MSCs. At the resting stage, it is entirely possible that AMD3100 may passively pass through cell membrane and target intracellular CXCR4 leading to MSC activation. Additionally, the absence of detectable CXCR4 on the cell surface does not necessarily rule out its surface expression. It is possible that current methodologies lack the sensitivity to capture its transient or rapidly cycling expression at the cell surface. Similar phenomenon have been described for other effector molecules, such as CTLA-4, which plays a functional role at the T-cell surface despite being more frequently detected intracellularly than on the membrane surface71. Nevertheless, future studies are required to test the functional role of intracellular or transiently recycling surface CXCR4 in modulating MSCs’ activation through AMD3100. Pharmacokinetic studies have shown that, immediately after infusion, plasma concentrations of AMD3100 peak at approximately 800–1000 ng/mL (around 1–2 µM) and then decline over time72. In the present study, we tested AMD3100 at concentrations of 1, 10, and 100µM in an in vitro model using primary human BM MSCs and some of these concentrations are higher in comparison to the physiologically identified levels. Several MSC responses were most pronounced at the highest concentration tested, while some of the responses such as CXCL9 and CXCL10 were detected at lower concentrations. Although these higher in vitro concentrations may appear supraphysiological and represent, in part, a limitation of the present in vitro study, the relatively short duration of exposure in these assays may partially compensate for the continuous and prolonged exposure observed in complex human physiological conditions. Another limitation of the present study is the limited number of MSC donors included in this in vitro analysis, which prevented the data correction for multiple testing statistical analysis. These can be addressed in future studies. Finally, our study provided insights that since AMD3100 can increase the secretome and responsive fitness of MSCs, it could potentially be tested for usage as a prelicensing agent to enhance the potency of MSCs in cellular therapy. Currently, MSCs are approved for allogeneic bone marrow HSCT complications such as Graft versus Host Disease73. Several strategies have been made to increase the potency of MSCs through pre activation prior to their infusion as cellular therapeutics74. Although clinical trials are needed to define the effectiveness of this strategy, the present report provided the rationale of including AMD3100 as one of the prelicensing agents that can be tested to increase the effectiveness of MSC therapy for auto and allo immune disorders of the bone marrow. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1